World Journal of
Pharmaceutical and Life Sciences

BUMETANIDE (NASAL SPRAY) DRUG

*Dr. R. Jona Methusala, K. Kalyani

ABSTRACT

Bumetanide nasal spray is a novel intranasal formulation designed to offer a rapid, effective, and convenient alternative to traditional oral and intravenous (IV) bumetanide for the treatment of edema associated with heart failure, liver disease, and kidney disease, including nephrotic syndrome. This nasal spray bypasses gastrointestinal absorption, which can be problematic in patients with fluid overload who often develop diuretic resistance to oral medications. Clinical trials have demonstrated that the nasal spray provides bioequivalence to oral and IV forms, with similar pharmacokinetics, diuretic effects, and urine output, but with faster absorption and more consistent bioavailability. The nasal spray is well-tolerated, with minimal nasal irritation, and offers outpatient use benefits by enabling earlier intervention and potentially reducing hospital admissions. This new mode of delivery can improve patient adherence, provide a user- friendly self-administration option, and bridge treatment gaps in fluid overload episodes for patients at home or outpatient settings. It represents a meaningful advancement in edema management by combining efficacy with convenience and safety, thus improving quality of life and reducing healthcare costs related to hospitalization for edema management.

[Full Text Article]   [Download Certificate]